Zepbound: what it is, who it's for, and how people pay for it

Zepbound is the weight-loss label of tirzepatide, the same molecule Eli Lilly sells as Mounjaro for type 2 diabetes. LillyDirect offers a self-pay pharmacy route alongside insurance options. A prescription, clinical suitability and the program’s purchase conditions still matter; the advertised medicine price does not include every possible visit or supply cost.

Zepbound is tirzepatide for weight and sleep apnea

Zepbound is the weight-management and sleep-apnea brand of tirzepatide, Eli Lilly's weekly injection that acts on two hormone receptors, GIP and GLP-1. Most older drugs in this class act on GLP-1 alone. FDA described tirzepatide’s dual GIP/GLP-1 receptor action in its approval materials.

The label explains the weight effect in plain terms. GLP-1 “is a physiological regulator of appetite and caloric intake,” and nonclinical studies suggest GIP adds to that ^[1]. Tirzepatide “decreases calorie intake,” the effect is “likely mediated by affecting appetite,” and it “lowers body weight with greater fat mass loss than lean mass loss.” It also slows stomach emptying, most after the first dose. The full mechanism, for both brands, is on our tirzepatide page.

Zepbound has two approved uses: weight and sleep apnea

The Zepbound label lists two uses. The first is reducing excess weight and keeping it off in adults with obesity, or with overweight plus at least one weight-related condition. The second is treating moderate to severe obstructive sleep apnea in adults with obesity ^[1]. When FDA approved the sleep apnea use on December 20, 2024, it called Zepbound the first medication for that condition ^[3].

Is Zepbound for diabetes or weight loss? Weight loss and sleep apnea. Zepbound does not have Mounjaro’s diabetes or cardiovascular-risk-reduction indications. People with type 2 diabetes can still be prescribed Zepbound for weight, and the label warns about low blood sugar in that group. Our Zepbound vs Mounjaro comparison shows where the two labels split.

Zepbound is for adults with a BMI of 30, or 27 with a weight-related condition

In practice, the weight label covers two groups. The trials defined obesity as a BMI of 30 or more. They also enrolled adults with a BMI of at least 27 but below 30 plus a weight-related condition, such as high blood pressure, abnormal cholesterol, sleep apnea or heart disease ^[1]. The sleep apnea use is for adults with obesity and moderate to severe apnea.

Some people shouldn't take it. The label rules Zepbound out for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, and for anyone who has had a serious allergic reaction to tirzepatide or a Zepbound ingredient. The label warns of fetal harm and directs discontinuation when pregnancy is recognized. It also does not recommend combining Zepbound with another tirzepatide product or a GLP-1 receptor agonist. It isn't approved for children, and the label doesn't recommend it for people with severe gastroparesis.

What about people with type 2 diabetes? They were studied too. In the label's Study 2, adults with type 2 diabetes and a BMI of 27 or more lost less weight than people without diabetes, and low blood sugar was more common: 4.2% on Zepbound vs 1.3% on placebo ^[1]. If you take insulin or a sulfonylurea, your prescriber may lower that dose when you start.

In trials, people lost about 15% to 21% of body weight

In SURMOUNT-1, adults with obesity, or overweight plus a weight-related complication, and no diabetes lost 15.0%, 19.5% and 20.9% of their weight on 5, 10 and 15 mg over 72 weeks, against 3.1% on placebo ^[9]. Half or more of people on the two higher doses lost at least 20% of their weight.

The head-to-head trial is the one people ask about. In SURMOUNT-5, tirzepatide beat semaglutide on weight and waist size at 72 weeks ^[10]. It was open-label and funded by Lilly. The tested doses were tirzepatide 10/15 mg versus semaglutide 1.7/2.4 mg; the result does not compare every available formulation or higher-dose semaglutide regimen. See Zepbound vs Wegovy for what that means in practice.

The sleep apnea result is just as striking. In SURMOUNT-OSA, participants not using positive airway pressure (PAP) saw breathing interruptions fall by 25.3 events an hour on tirzepatide vs 5.3 on placebo; in the trial enrolling PAP users, the drop was 29.3 vs 5.5 ^[11]. Those results are what FDA based the sleep apnea approval on.

What happens when you stop Zepbound? SURMOUNT-4 is clear. After 36 weeks of treatment, people moved to placebo regained 14.0% of their weight over the next year, while those who stayed on tirzepatide lost another 5.5% ^[12]. These are group averages in participants who reached randomization after the lead-in, not a prediction that every person returns to baseline. At week88, the placebo group still averaged 9.9% below its original weight, versus 25.3% for continued treatment.

Zepbound comes as a single-dose pen, two kinds of vial and a KwikPen

Zepbound comes in four presentations, all in the same six strengths from 2.5 to 15 mg ^[1]. Two hold one dose. Two hold four. The difference that matters most to your wallet is where each one is sold.

Storage differs too. The label allows a single-dose pen or vial to sit unrefrigerated, at no more than 86°F, for up to 21 days in total, and it says never to use Zepbound that has frozen ^[1]. For an in-use multi-dose vial or KwikPen, discard at the earliest of 30 days at room temperature, 30 days after first use, or 4 weekly doses. These limits are presentation-specific; ask your pharmacist to resolve any storage excursion.

Is there a Zepbound pill? No. Zepbound is only an injection. Lilly's GLP-1 pill is Foundayo, a different molecule called orforglipron; it is a separate product. Our Foundayo vs Zepbound comparison covers the trade-offs.

The label starts everyone at 2.5 mg and allows up to 15 mg

The Zepbound label starts every patient at 2.5 mg once a week for four weeks and says that dose “is for treatment initiation and is not approved as a maintenance dosage” ^[1]. The maximum is 15 mg once a week. Your prescriber sets the steps in between, based on how you're doing and how well you tolerate it.

Two things follow for cost. LillyDirect’s lowest advertised price applies to the starting strength, while the listed maintenance-strength offers cost more. A specific prescription and refill schedule determine the applicable offer; these are 28-day supplies, not calendar months. Our Zepbound dosage guide explains what the label says about each strength.

Gastrointestinal effects are common; nausea, vomiting and diarrhea often cluster during escalation

Zepbound's most common side effects are gastrointestinal, and it carries the class boxed warning about thyroid C-cell tumors in rodents. In the label's pooled weight trials, stomach side effects hit 56% of people at every dose against 30% on placebo, and the label says most nausea, vomiting and diarrhea “occurred during dose escalation and decreased over time” ^[1].

The label's warnings include severe stomach reactions, kidney injury from dehydration, gallbladder disease, pancreatitis, allergic reactions, low blood sugar in people with diabetes, diabetic eye complications and aspiration during anesthesia. It also says Zepbound can make birth-control pills less reliable for a while after starting and after each dose increase, so ask your prescriber about that if it applies to you.

For the details, see Zepbound side effects, whether Zepbound causes constipation and the molecule-wide guide to tirzepatide side effects.

LillyDirect self-pay offers start at $299 per 28 days

LillyDirect advertises eligible Zepbound vials and KwikPens for cash from $299 per 28-day supply ^[6]. The 7.5 to 15 mg Journey Program price of $449 requires a refill within 45 days and applicable eligibility. Miss that window and the price jumps to $499 for 7.5 mg or $699 for 10, 12.5 or 15 mg.

With insurance, the math changes. Eligible commercially insured adults with Zepbound single-dose-pen coverage may pay as little as $25 for a 1-, 2- or 3-month fill under Lilly’s savings terms, subject to maximum savings and other restrictions. The program defines these as 28, 56 or 84 days and excludes government-insured patients ^[7]. On Medicare, CMS runs the Medicare GLP-1 Bridge, a demonstration that began July 1, 2026 with a $50 copay for eligible Part D members outside the usual Part D benefit flow; its copay does not count toward the Part D out-of-pocket threshold ^[8]. Lilly says Zepbound for weight management is covered there for no more than $50 a month, subject to clinical criteria ^[7].

For every option in one place, read our Zepbound cost guide, and use the monthly cost calculator to compare a program's billing with LillyDirect's price.

Zepbound vs Wegovy, Ozempic and Mounjaro, in brief

Zepbound and Wegovy injection are weekly brands labeled for weight management. Zepbound produced more weight loss head to head, while Wegovy has separate cardiovascular indications and an injection-only indication for adults with noncirrhotic MASH with moderate to advanced fibrosis. Form, population and indication must be checked separately. Ozempic is semaglutide for type 2 diabetes, and Mounjaro contains tirzepatide, with diabetes and certain adult cardiovascular indications. Each comparison has its own page: Zepbound vs Wegovy, Ozempic vs Zepbound and Zepbound vs Mounjaro.

Compounded tirzepatide is not Zepbound

Compounded tirzepatide is pharmacy-made and is not Zepbound or an FDA-approved generic. FDA does not conduct premarket review of compounded drugs for safety, effectiveness or quality. Applicable 503A/503B conditions and restrictions on essentially copying commercially available drugs still matter ^[5]. FDA ended the shortage that allowed mass copies in December 2024.

Because some telehealth programs still offer it for less than LillyDirect's price, it's worth knowing the difference before you compare prices. Our guides cover compounded tirzepatide vs Zepbound, whether compounded tirzepatide is still available and the compounded tirzepatide basics, and the compounded tirzepatide board scores the programs.

The cited Zepbound trials do not validate an ad-hoc microdose regimen

The label calls 2.5 mg an initiation dose rather than a maintenance dose. The cited pivotal trials do not establish the effectiveness or safety of an individualized small-dose or extended-interval schedule. Some programs market small or spaced-out doses. The evidence, and the open questions, are in our guide to microdosing tirzepatide.

You need a prescription, then LillyDirect or a pharmacy fills it

Zepbound needs a valid prescription from a licensed healthcare provider. LillyDirect says your doctor can send that prescription to LillyDirect Pharmacy, and its page also points to outside virtual care for people who don't have a prescriber ^[6]. A telehealth service may offer brand prescribing, but verify its current product and pharmacy arrangements before paying.

Telehealth companies don't make Zepbound. They provide the visit and the prescription, and the drug comes from Lilly through a pharmacy. What you pay them on top of the medication varies a lot.

Before choosing a service, compare its consultation and membership charges separately from the pharmacy’s medicine price. A provider review can explain the care model, but it does not replace a current written Zepbound quote. Use the coverage-cost worksheet to separate medicine, plan payments and service fees.